GlassScriptPhysician profile
Kirsten Dericks
NPI 1689353930
$4,097.39
in general payments reported to CMS, 2019-2025
22 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,761 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,884 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,884.41 |
| Education | $212.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $601.70 | 2024-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $569.93 | 2024-2025 | Caplyta |
| Abbvie INC. | $529.01 | 2024-2025 | |
| Tris Pharma INC | $394.83 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Alkermes, INC. | $363.52 | 2024-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $247.83 | 2024-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $246.91 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $244.46 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $201.91 | 2024-2025 | Fanapt, Hetlioz |
| Indivior INC. | $149.60 | 2024-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $115.70 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $76.68 | 2025 | |
| Uswm, LLC | $76.23 | 2024 | Lucemyra |
| Noven Therapeutics, LLC | $68.72 | 2025 | Secuado, Xelstrym |
| Gilead Sciences, INC. | $40.26 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $39.44 | 2024-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.09 | 2025 | Rejoyn |
| Eisai INC. | $27.41 | 2024 | |
| Lilly USA, LLC | $20.82 | 2025 | Zepbound |
| Almatica Pharma LLC | $16.70 | 2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $16.66 | 2025 | Qelbree |
| Neos Therapeutics, LP | $15.98 | 2025 | Exxua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirsten Dericks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.